Navigation Links
REMEDEE Study Meets Primary Endpoint: OrbusNeich's Combo™ Dual Therapy Stent Is Non-Inferior to DES
Date:11/14/2011

HONG KONG, Nov. 14, 2011 /PRNewswire/ -- OrbusNeich today announced that results from the REMEDEE study (Randomized Evaluation of an abluMinal sirolimus coatED bio-Engineered stEnt) confirmed that the Combo Dual Therapy Stent is non-inferior to the TAXUS® Liberte® paclitaxel-eluting stent, with respect to in-stent late lumen loss at nine-month angiographic follow-up. The results were presented by Michael Haude, M.D., director of Medical Clinic I at the Lukaskrankenhaus in Neuss, Germany, last week during the Late Breaking Clinical Trials and First Report Investigations Session at Transcatheter Cardiovascular Therapeutics (TCT) 2011 in San Francisco.

The Combo Stent, the world's first dual therapy stent (DTS), combines an abluminal biodegradable sirolimus elution for the regulation of hyperplasia with Genous™, OrbusNeich's proven endothelial progenitor cell (EPC) capture technology, to accelerate re-endothelialization. The study's primary objective was to demonstrate the safety and effectiveness of the Combo Stent compared to the TAXUS Liberte paclitaxel-eluting stent in patients with symptomatic, ischemic heart disease due to a stenotic lesion located in a native coronary artery. The study's primary endpoint was non-inferiority based on in-stent late lumen loss at nine months.

At nine-month angiographic follow-up, the in-stent late lumen loss for the Combo Dual Therapy Stent was 0.39 +/- 0.45 mm compared to 0.44 +/- 0.56 mm for the TAXUS drug eluting stent (DES).

"This first clinical experience with the Combo Dual Therapy Stent confirms that Combo achieves an antiproliferative effect and safety profile similar to that of current DES," said Prof. Haude. "However, the real differentiating factor for Combo is the Genous pro-healing technology. Using intravascular ultrasound (IVUS) and optical coherence tomography (OCT) imaging, we saw superb homo
'/>"/>

SOURCE OrbusNeich
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. BioDelivery Sciences Initiates Confirmatory Pharmacokinetic Study of BEMA Buprenorphine/Naloxone Compared to Suboxone
2. NeuroDerm Announces Positive Results of a Phase II Study of ND0611 Dermal Patch in Patients with Parkinsons Disease
3. Micell Technologies Announces Positive Preliminary Data from DESSOLVE I Study of MiStent® Sirolimus Drug Eluting Coronary Stent System
4. ChemoCentryx Reports Clinical Efficacy for CCX354, a Novel CCR1 Inhibitor in a Phase II Study in Patients with Rheumatoid Arthritis
5. Boston Scientific Carotid WALLSTENT® Found Safe in Study of High Surgical Risk Patients in Routine Clinical Practice
6. Breaking Study: ICU Medical, Inc. ChemoClave® System Costs Less to Implement than any Closed System Transfer Device for the Safe Handling of Hazardous Drugs
7. Positive Interim Results from Interferon-Free Phase 2b SOUND-C2 Study with Boehringer Ingelheims Two Investigational HCV Direct Acting Antivirals Presented at AASLD
8. New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T
9. Study Calls for Modification of CMS Conditions of Participation to Preserve Access to Life-Saving Liver Transplantations under Less than Optimal Conditions
10. Tibotec to Present Final Safety and Efficacy Results From Phase 2b PILLAR Study of Once-Daily TMC435 in Late-Breaker at AASLD
11. Study Shows Efficacy of C1-Esterase Inhibitor Concentrate in Treating Acute Attacks of Hereditary Angioedema in Children and Adolescents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... , Oct. 30, 2014   BioLife Solutions ... developer, manufacturer and marketer of proprietary clinical grade ... and precision thermal shipping products for cells ... quarter 2014 financial results will be released on Thursday, ... a conference call and live webcast at 1:30 p.m. ...
(Date:10/30/2014)... 30, 2014 Extensiv ... Aufbau von Kuhmilchverträglichkeit     Kuhmilchproteinallergie (KMPA) ... Säuglingen und Kleinkindern. Der bisher übliche Umgang ... der Babys bzw. deren stillenden Mütter Milchproteine ... sich bei einer beträchtlichen Anzahl von Kindern ...
(Date:10/30/2014)... , Oct. 30, 2014 Today, DripDrop, ... announced that it was awarded a two-year contract, ... services company that serves the more than 100,000 ... Hospital Association and Provista.  DripDrop ... feedback from member hospitals who attended the recent ...
Breaking Medicine Technology:BioLife Solutions to Report Financial Results for Third Quarter 2014 and Provide Business Update on November 6, 2014 2Experten präsentieren neuste Forschungsergebnisse auf dem Allergy Day 2Experten präsentieren neuste Forschungsergebnisse auf dem Allergy Day 3DripDrop Partners With Novation To Help Hospitals Address I.V. Saline Solution Shortages; ORS Product Used For Ebola Outbreak 2DripDrop Partners With Novation To Help Hospitals Address I.V. Saline Solution Shortages; ORS Product Used For Ebola Outbreak 3DripDrop Partners With Novation To Help Hospitals Address I.V. Saline Solution Shortages; ORS Product Used For Ebola Outbreak 4
... MEETING, Pa., Feb. 16, 2012 ECRI Institute ... approaches to improving patient care, has released CT ... to give hospital leaders an at-a-glance overview of the ... popular makes and models, to average pricing, and most ...
... a leading pharmaceutical CRO, announced today that Robert Gwozdz, ... efforts.  According to Mark Mitchnick, the company,s CEO, "PSI ... across many dosage forms and drug types.  For instance, ... molecules of which about 80% fall into BCS II.  ...
Cached Medicine Technology:ECRI Institute Guides Hospital Decision-Makers in the Purchase of CT Scanning Systems 2ECRI Institute Guides Hospital Decision-Makers in the Purchase of CT Scanning Systems 3Particle Sciences Hires Robert Gwozdz to Head Oral Formulation 2
(Date:10/30/2014)... Global prebiotics market is expected to ... new study by Grand View Research, Inc. Positive outlook ... and fat free products owing to increased concerns over ... over the forecast period. , View full report with ... beverage was the largest application segment with market volume ...
(Date:10/30/2014)... South Carolina (PRWEB) October 30, 2014 ... and should be more vigorously exercised to help maintain ... recently authored the book ‘Dementia Express: Lose Your Memory ... book uses counterintuitive reasoning and sometimes conflicting attitudes to ... course for the mind, a reader must decipher the ...
(Date:10/30/2014)... Sound Telecom, a leader in the call center industry, just ... they wonder, “Should I use an answering service?” The graphic ... a series of yes or no questions that ultimately ends ... many considerations and scenarios that come into play when deciding ... This decision infographic serves as a bit of a map ...
(Date:10/30/2014)... Amy Norton HealthDay ... Exposure to a common plastics, chemical during pregnancy may have ... hints. Researchers found that baby boys born to moms ... have a shorter anogenital distance -- the space between the ... and it,s considered a marker of exposure to androgens ("male" ...
(Date:10/30/2014)... -- Eating a low-carb, high-fat diet could help control ... research. A review of five studies found ... on foods like bacon, eggs, heavy cream, butter, fish ... whose condition doesn,t improve with medication. "We need ... epilepsy whose seizures are not stopped by medications," study ...
Breaking Medicine News(10 mins):Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 2Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 3Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 4Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 5Health News:‘Dementia Express’ Offers Contradictory and Sometimes Reverse Thinking, All to Keep its Reader on Their Toes With an Active Mind. 2Health News:Sound Telecom Produces Decision Infographic to Aid Businesses 2Health News:Plastics' Chemical May Affect Baby Boys' Genital Development 2Health News:Plastics' Chemical May Affect Baby Boys' Genital Development 3Health News:High-Fat, Low-Carb Diet May Help With Tough-to-Treat Epilepsy 2Health News:High-Fat, Low-Carb Diet May Help With Tough-to-Treat Epilepsy 3
... NHS Hospital Trusts on Sunday, thankfully no patient data ... in charge of the IT services in NHS conveyed ... were interrupted due to the failure of equipment that ... will be maintained till ,the system is restored. ...
... problems may face the risk of several underlying medical complications, ... ,A team from the New England Research Institute in Massachusetts ... over 15 years and looked at markers for metabolic syndrome, ... edition of Daily Mail. ,These markers include raised ...
... (HPV) vaccine which is said to prevent about 75 percent ... and even women already exposed to the disease causing virus//, ... papillomavirus (HPV) has been approved for women aged 9 to ... and gynecology at the University of California-Irvine, argued that with ...
... 9,000 Danish residents revealed that a specific mutation in the ... breast cancer in her lifetime. The study, which was the ... the cancer risk associated with it, in the general population, ... Journal of Clinical Oncology. ,"Our study shows ...
... stop overdoses in heroin addicts. Hence many needle exchange ... news follows the deaths of at least 400 people ... ,Prevention Point Philadelphia, a nonprofit organization responsible for needle ... of naloxone prescriptions through a physician. "If people have ...
... the University of Florida, Gainesville, mice based experiments were found ... of the heart.// , This new technique was ... that damages the heart. The findings, published July 27 in ... studies in humans that could begin as soon as early ...
Cached Medicine News:Health News:Demand for More Widespread Use of HPV Vaccine 2Health News:Demand for More Widespread Use of HPV Vaccine 3Health News:CHEK 2 Gene Mutation Triples Breast Cancer Risk 2Health News:Gene Therapy Technique for Inherited Heart Problems in The Pipeline 2Health News:Gene Therapy Technique for Inherited Heart Problems in The Pipeline 3Health News:Gene Therapy Technique for Inherited Heart Problems in The Pipeline 4
IMMCO ANA Elisa meets the guidelines for the laboratory diagnosis and monitoring of systemic autoimmune rheumatic diseases intended for the use of clinical pathologists and laboratory physicians....
An enzyme-linked immuno-sorbent assay for the detectionand quantitation of anti-tissue Transglutaminase in serum of patients with Celiac Disease and Dermatitis Herpetiformis....
Jerome Halo Traction Units provide optimum immobilization for unstable injuries of the spine. The Generation 80 superstructure is available with either 2-point (serrated disk), or 3-point (flexion/ex...
... Boston Scoliosis Brace™ for neuromuscular ... a lightweight, soft, and easy ... maximum comfort. The Soft ... of non-cracking orthopedic grade copolymer ...
Medicine Products: